Free Trial

ProQR Therapeutics (PRQR) Competitors

ProQR Therapeutics logo
$2.79 +0.07 (+2.57%)
As of 11:48 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

PRQR vs. COLL, PHAR, BCAX, RAPP, CRON, PGEN, XNCR, OCS, ORKA, and BGM

Should you be buying ProQR Therapeutics stock or one of its competitors? The main competitors of ProQR Therapeutics include Collegium Pharmaceutical (COLL), Pharming Group (PHAR), Bicara Therapeutics (BCAX), Rapport Therapeutics (RAPP), Cronos Group (CRON), Precigen (PGEN), Xencor (XNCR), Oculis (OCS), Oruka Therapeutics (ORKA), and BGM Group (BGM). These companies are all part of the "pharmaceutical products" industry.

ProQR Therapeutics vs. Its Competitors

ProQR Therapeutics (NASDAQ:PRQR) and Collegium Pharmaceutical (NASDAQ:COLL) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, valuation, dividends and risk.

Collegium Pharmaceutical has a net margin of 5.13% compared to ProQR Therapeutics' net margin of -238.52%. Collegium Pharmaceutical's return on equity of 97.28% beat ProQR Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
ProQR Therapeutics-238.52% -61.25% -28.13%
Collegium Pharmaceutical 5.13%97.28%13.87%

In the previous week, ProQR Therapeutics and ProQR Therapeutics both had 5 articles in the media. Collegium Pharmaceutical's average media sentiment score of 0.97 beat ProQR Therapeutics' score of -0.13 indicating that Collegium Pharmaceutical is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ProQR Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Collegium Pharmaceutical
2 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

ProQR Therapeutics has a beta of 0.23, suggesting that its share price is 77% less volatile than the S&P 500. Comparatively, Collegium Pharmaceutical has a beta of 0.65, suggesting that its share price is 35% less volatile than the S&P 500.

32.7% of ProQR Therapeutics shares are owned by institutional investors. 8.4% of ProQR Therapeutics shares are owned by insiders. Comparatively, 2.5% of Collegium Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Collegium Pharmaceutical has higher revenue and earnings than ProQR Therapeutics. ProQR Therapeutics is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ProQR Therapeutics$20.46M14.35-$30.04M-$0.46-6.07
Collegium Pharmaceutical$631.45M1.79$69.19M$1.0434.48

ProQR Therapeutics currently has a consensus price target of $8.00, indicating a potential upside of 186.74%. Collegium Pharmaceutical has a consensus price target of $42.33, indicating a potential upside of 18.05%. Given ProQR Therapeutics' higher possible upside, equities analysts clearly believe ProQR Therapeutics is more favorable than Collegium Pharmaceutical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ProQR Therapeutics
2 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.70
Collegium Pharmaceutical
0 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
2 Strong Buy rating(s)
3.00

Summary

Collegium Pharmaceutical beats ProQR Therapeutics on 11 of the 16 factors compared between the two stocks.

Get ProQR Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for PRQR and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRQR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PRQR vs. The Competition

MetricProQR TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$293.54M$3.43B$6.17B$10.63B
Dividend YieldN/A2.24%5.72%4.86%
P/E Ratio-6.0723.2329.5828.04
Price / Sales14.35469.60572.92128.21
Price / CashN/A45.5937.1261.42
Price / Book3.0710.3012.016.50
Net Income-$30.04M-$52.53M$3.33B$276.73M
7 Day Performance-0.36%-0.07%-0.41%-0.21%
1 Month Performance29.17%10.93%5.79%1.39%
1 Year Performance-20.06%14.47%65.67%32.88%

ProQR Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PRQR
ProQR Therapeutics
2.2705 of 5 stars
$2.79
+2.6%
$8.00
+186.7%
-28.0%$293.54M$20.46M-6.07180
COLL
Collegium Pharmaceutical
3.7601 of 5 stars
$32.04
flat
$42.33
+32.1%
-1.3%$1.01B$631.45M30.81210News Coverage
PHAR
Pharming Group
2.7583 of 5 stars
$14.61
+2.4%
$30.00
+105.3%
+46.6%$977.71M$297.20M-112.38280Gap Up
BCAX
Bicara Therapeutics
2.6765 of 5 stars
$18.51
+4.1%
$31.86
+72.1%
-27.4%$971.01MN/A-5.8432
RAPP
Rapport Therapeutics
3.0004 of 5 stars
$26.19
-1.2%
$35.33
+34.9%
-1.3%$967.20MN/A-10.48N/A
CRON
Cronos Group
1.4028 of 5 stars
$2.55
+1.6%
N/A+5.2%$961.06M$117.61M51.00450Positive News
PGEN
Precigen
4.3424 of 5 stars
$3.21
+2.9%
$8.25
+157.0%
+317.2%$929.68M$3.92M-7.64190Gap Up
XNCR
Xencor
3.7866 of 5 stars
$13.96
+7.1%
$24.22
+73.5%
-37.4%$929.34M$110.49M-5.82280
OCS
Oculis
2.4073 of 5 stars
$21.00
-0.4%
$41.00
+95.2%
+34.1%$920.84M$780K-7.872Short Interest ↑
ORKA
Oruka Therapeutics
2.8442 of 5 stars
$25.50
+4.1%
$41.80
+63.9%
-11.7%$917.17MN/A-9.07N/A
BGM
BGM Group
0.5299 of 5 stars
$9.49
+1.7%
N/A+22.1%$907.08M$25.10M0.00298News Coverage
Short Interest ↑
Gap Up

Related Companies and Tools


This page (NASDAQ:PRQR) was last updated on 10/23/2025 by MarketBeat.com Staff
From Our Partners